TY  - GEN
AU  - Bonecker,Simone
AU  - Carvalho,Gabriela
AU  - Dobbin,Jane
AU  - Zalcberg,Ilana
AU  - Schaffel,Rony
TI  - Early molecular response ≤1% has strong prognostic impact for CML patients that switch to second-line therapy with BCR-ABL1 ≤10% and no major molecular response
SN  - 1365-2141
PY  - 2020///0501
KW  - Adult
KW  - Aged
KW  - Antineoplastic Agents
KW  - therapeutic use
KW  - Dasatinib
KW  - Drug Substitution
KW  - Female
KW  - Fusion Proteins, bcr-abl
KW  - metabolism
KW  - Humans
KW  - Imatinib Mesylate
KW  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive
KW  - drug therapy
KW  - Male
KW  - Middle Aged
KW  - Pyrimidines
KW  - Survival Analysis
KW  - Young Adult
N1  - Publication Type: Letter
UR  - https://doi.org/10.1111/bjh.15611
ER  -